



ASX Announcement

23 September 2019

Leading Australian and United States Hospital Collaboration to Trial Optiscan's Cancer Imaging System

Highlights

- **The Melbourne Dental School (University of Melbourne) is seeking ethics approval for the use of Optiscan's clinical imaging system as part of a human clinical trial to diagnose cancerous change in oral mucosa at the earliest possible stage (Oral Cancer Trial)**
- **Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Centre and Australian Centre for Oral Oncology Research & Education (Collaborators) are collaborators in the Oral Cancer Trial**
- **2nd Oral Cancer Clinical Trial by World-Leading Hospitals targeting Oral Cancer Screening using the Optiscan system**

Optiscan Imaging Limited (ASX: OIL, Optiscan, the Company) is pleased to advise that the Melbourne Dental School (University of Melbourne) is seeking ethics approval for a clinical trial "intended to diagnose cancerous change in oral skin growth at the earliest possible stage, identifying new areas of abnormality or changes in previous oral lesions". The Oral Cancer Trial aims to develop diagnostic tools including confocal laser scanning microscopy utilising an Optiscan system to supplement the current practice of clinical oral examination and histopathological diagnosis.

Oral cancer is one of the most common cancers globally with an estimated 450,000 new cases of oral and oropharyngeal cancer per annum. Early detection of malignant changes increases survival rate dramatically, however, early-stage oral cancer, is currently often difficult to recognize, as it clinically appears very similar to benign lesions.

The project, being led by the Melbourne Dental School, aims to create the foundation to connect clinical, imaging and molecular findings in the development of oral squamous cell carcinoma (OSCC) in oral mucosal conditions with malignant potential, collectively termed Oral Potentially Malignant Disorders (OPMDs). The most common OPMDs are leukoplakia and oral lichen planus or oral lichenoid lesions.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

In addition to the highly regarded Melbourne Dental School, world-leading cancer hospitals and research institutions the Royal Melbourne Hospital, Peter MacCallum Cancer Centre, the New York based Memorial Sloan Kettering Cancer Centre and the Australian Centre for Oral Oncology Research & Education are collaborators in the Oral Cancer Trial.

The use of an Optiscan system in this Oral Cancer Trial as well as the previously announced (21 August 2019) trial by Memorial Sloan Kettering Cancer Centre provides strong validation of the imaging capability of the Optiscan system and potential use as a virtual digital biopsy tool in oral cancer screening and surgical tumour margin detection. Throughout and following this Oral Cancer Trial, Optiscan will receive valuable data to support its application for regulatory approvals of the Optiscan clinical system. Grant funding for the Oral Cancer Trial will be sought including for the use of the Optiscan system.

Optiscan's Executive Chairman Darren Lurie, said:

“Having two clinical trials in oral cancer screening with such internationally renowned hospitals is strong validation of the opportunity for Optiscan to change current practices in oral cancer screening. We expect the trial will provide strong support in our evolving plans for Optiscan's clinical system and in the regulatory approvals for use in oral cancer screening and surgical tumour margin detection. We remain focused on bringing our breakthrough technology to market.

Corporate Enquiries:

Darren Lurie
Executive Chairman – Optiscan Imaging
E: dlurie@optiscan.com

Investor & Media Enquiries:

Peter Taylor
NWR Communications
E: peter@nwrcommunications.com.au

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia